RT Journal Article
SR Electronic
T1 Association between Participation in Government Subsidy Program for Domestic Travel and Symptoms Indicative of COVID-19 Infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.03.20243352
DO 10.1101/2020.12.03.20243352
A1 Atsushi Miyawaki
A1 Takahiro Tabuchi
A1 Yasutake Tomata
A1 Yusuke Tsugawa
YR 2020
UL http://medrxiv.org/content/early/2020/12/19/2020.12.03.20243352.abstract
AB Importance As countermeasures against the economic downturn caused by the coronavirus 2019 (COVID-19) pandemic, many countries have introduced or considering financial incentives for people to engage in economic activities such as travel and use restaurants. Japan has implemented a large-scale, nationwide government-funded program that subsidizes up to 50% of all travel expenses since July 2020 with the aim of reviving the travel industry. However, it remains unknown as to how such provision of government subsidies for travel impacted the COVID-19 pandemic.Objective To investigate the association between participation in government subsidies for domestic travel in Japan and the incidence of COVID-19 infections.Design, Setting, and Participants Using the data from a large internet survey conducted between August 25 and September 30, 2020, in Japan, we examined whether individuals who used subsidies experienced a higher likelihood of symptoms indicative of the COVID-19 infection.Exposure Participation in the government subsidy program for domestic travel.Main Outcomes and Measures Five symptoms indicative of the COVID-19 infection (high fever, sore throat, cough, headache, and smell and taste disorder) within the past one month of the survey.Results Of the 25,482 respondents (50.3% [12,809] women; mean [SD] age, 48.4 [17.4] years), 3,289 (12.9%) participated in the subsidy program at the time of survey. After adjusting for potential confounders, we found that participants in the subsidy program exhibited higher incidence of high fever (adjusted rate, 4.8% for participants vs. 3.7% for non-participants; adjusted odds ratio [aOR], 1.90; 95%CI, 1.42-2.54; p<0.001), sore throat (19.8% vs. 11.3%; aOR, 2.09; 95%CI, 1.37-3.20; p=0.002), cough (19.1% vs. 11.2%; aOR 1.96; 95%CI, 1.27-3.02; p=0.007), headache (29.1% vs. 25.5%; aOR, 1.24; 95%CI, 1.07-1.43; p=0.007), and smell and taste disorder (2.6% vs. 1.8%; aOR 1.98; 95%CI; 1.15-3.40; p=0.01) compared with non-participants.Conclusion and Relevance The participants of government subsidies for domestic travel experienced a higher incidence of symptoms indicative of the COVID-19 infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Japan Society for the Promotion of Science (JSPS) KAKENHI Grants [grant number 17H03589;19K10671;19K10446;18H03107; 18H03062], the JSPS Grant-in-Aid for Young Scientists [grant number 19K19439], Research Support Program to Apply the Wisdom of the University to tackle COVID-19 Related Emergency Problems, University of Tsukuba, and Health Labour Sciences Research Grant [grant number 19FA1005;19FG2001]. Dr. Miyawaki was supported by the JSPS KAKENHI Grants [grant number 20K18956] and the Social Science Research Council Abe Fellowship. Dr. Tsugawa was supported by the National Institute of Health (NIH)/NIMHD Grant R01MD013913 and NIH/NIA Grant R01AG068633.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board of the Osaka International Cancer Institute (No. 20084).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.